Immune checkpoint blockade therapy, specifically anti-programmed cell death protein 1 (PD1) therapy (pembrolizumab and nivolumab), has shown promise in various forms of KS [318,319]. This evidence concerns the gene PDCD1 and Kaposi's sarcoma.